Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Gene Ther ; 17(10): 1279-87, 2010 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-20485380

RESUMEN

Both atherosclerosis and arterial interventions induce oxidative stress mediated in part by nicotinamide adenine dinucleotide phosphate (NADPH) oxidases that have a pivotal role in the development of neointimal hyperplasia and restenosis. For small interfering RNA (siRNA) targeting of the NOX2 (Cybb) component of the NADPH oxidase to prevent restenosis, gene transfer with viral vectors is effective, but raises safety issues in humans. We developed a new approach using the amino-acid-based nanoparticle HB-OLD7 for local delivery of siRNA targeting NOX2 to the arterial wall. siRNA-nanoparticle complexes were transferred into the regional carotid artery walls after angioplasty in an atherosclerotic rat model. Compared with angioplasty controls, Cybb gene expression (measured by quantitative reverse transcriptase-PCR) in the experimental arterial wall 2 weeks after siRNA was reduced by >87%. The neointima-to-media-area ratio was decreased by >83%, and the lumen-to-whole-artery area ratio was increased by >89%. Vital organs showed no abnormalities and splenic Cybb gene expression showed no detectable change. Thus, local arterial wall gene transfer with HB-OLD7 nanoparticles provides an effective, nonviral system for efficient and safe local gene transfer in a clinically applicable approach to knock down an NADPH oxidase gene. Local arterial knockdown of the Cybb gene significantly inhibited neointimal hyperplasia and preserved the vessel lumen without systemic toxicity.


Asunto(s)
Aterosclerosis/terapia , Glicoproteínas de Membrana/antagonistas & inhibidores , NADPH Oxidasas/antagonistas & inhibidores , Nanopartículas/administración & dosificación , ARN Interferente Pequeño/administración & dosificación , Animales , Aterosclerosis/genética , Aterosclerosis/patología , Vectores Genéticos/administración & dosificación , Hiperplasia/metabolismo , Hiperplasia/patología , Masculino , Glicoproteínas de Membrana/genética , Ratones , Modelos Animales , NADPH Oxidasa 2 , NADPH Oxidasas/genética , Neointima/metabolismo , Neointima/patología , ARN Interferente Pequeño/genética , Ratas , Ratas Sprague-Dawley , Recurrencia
2.
J Lab Clin Med ; 86(1): 140-51, 1975 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-1151136

RESUMEN

A highly purified erythropoietin (ESF) preparation (12,000 units per milligram of protein) was labeled with Na'125I using the Chloramine-T method. Undamaged immunoreative labeled ESF was separated from the damaged, nonimmunologically receiveESF by Sephadex G-150 fractionation. This undamaged immunreactive ESF was usedin radioimmunoassay for human erythropoietin. Separation of bound from free antigen was acheived using the double-antibody technique. Approximately 55 per cent binding wasobserved at an antiserum dilution of 1:1500. This assay appears to be sensitive enough to detect as little as 0.025 milliunits of the International Reference Preparation erythropoietin. The estimated levels of thid hormone in normal and anemic uremic human subjects suggests that immunoreactive serum erythropoietin levels are elevated above normal in anemia of uremia.


Asunto(s)
Eritropoyetina/análisis , Radioinmunoensayo/métodos , Anemia/sangre , Animales , Electroforesis de las Proteínas Sanguíneas , Cromatografía , Relación Dosis-Respuesta a Droga , Humanos , Radioisótopos de Yodo , Marcaje Isotópico , Conejos , Uremia/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA